Shenzhen Neptunus Bioengineering Co., Ltd. (SHE:000078)

Market Cap	6.87B
Revenue (ttm)	29.60B
Net Income (ttm)	-1.21B
Shares Out	2.63B
EPS (ttm)	-0.46
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	136,253,345
Average Volume	33,543,237
Open	2.360
Previous Close	2.520
Day's Range	2.360 - 2.760
52-Week Range	2.070 - 3.190
Beta	0.48
RSI	69.44
Earnings Date	Aug 29, 2025

About SHE:000078

Shenzhen Neptunus Bioengineering Co., Ltd. engages in the research and development, production, and sales of Chinese patent medicines, infusion products, and western medicine preparations in China. The company provides oryzanol tablets, chlorpheniramine tablets, chlorpheniramine maleate tablets, and rifampicin capsules, as well as technical support for generic drug quality consistency evaluation and other medical research and development work. It also distributes drugs, medical devices, and other medical supplies; and provides value-added servi...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1989
• Employees: 8,264
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 000078

Financial Performance

In 2024, SHE:000078's revenue was 30.32 billion, a decrease of -16.75% compared to the previous year's 36.42 billion. Losses were -1.19 billion, -29.38% less than in 2023.